Background Comorbidity is highly prevalent between substance use disorders (SUDs),
mood and anxiety disorders. We conducted a systematic review and meta-analysis to …

BackgroundControversy remains as to whether cannabis acts as a causal risk factor for
schizophrenia or other functional psychotic illnesses. AimsTo examine critically the evidence …

Purpose The present study established the national prevalence of substance use disorders
(SUDs) among Danish psychiatric patients. Furthermore, patients with SUDs and those …

Background. Schizophrenia has a high natural mortality of a largely environmental
aetiology. There is, however, little research about possible risk factors. This study measured …

Hyperprolactinaemia is an important but neglected adverse effect of antipsychotic
medication. It occurs frequently with conventional antipsychotics and some atypical …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

BackgroundCannabis is commonly regarded as an innocuous drug and the prevalence of
lifetime and regular use has increased in most developed countries. However, accumulative …

BackgroundImproved management of mental illness and substance misuse comorbidity is a
National Health Service priority, but little is known about its prevalence and current …

This paper reviews the literature on disengagement from mental health services examining
how the terms engagement and disengagement are defined, what proportion of patients …

Around half of all patients with schizophrenia are thought to abuse drugs or alcohol and
there is good evidence to suggest that they have poorer outcomes than their non substance …